Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-? and IFN inducer - 22/09/20
, Kwok-Yung Yuen c, d, ⁎
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | SARS-CoV-2 infection was more robust than SARS-CoV in Calu3. In contrast, SARS-CoV infected intestinal epithelial cells more efficiently. |
• | SARS-CoV-2 infection launched an attenuated interferon and pro-inflammatory cytokines/chemokines response in both Calu3 and Caco2 cells, despite robust virus infection and propagation. |
• | SARS-CoV-2 was more sensitive to IFNβ and poly(I:C) pretreatment than that of SARS-CoV. |
Summary |
Objectives |
Respiratory and intestinal tract are two primary target organs of SARS-CoV-2 infection. However, detailed characterization of the host-virus interplay in infected human lung and intestinal epithelial cells is lacking.
Methods |
We utilized immunofluorescence assays, flow cytometry, and RT-qPCR to delineate the virological features and the innate immune response of the host cells against SARS-CoV-2 infection in two prototype human cell lines representing the human lung (Calu3) and intestinal (Caco2) epithelium when compared with SARS-CoV.
Results |
Lung epithelial cells were significantly more susceptible to SARS-CoV-2 compared to SARS-CoV. However, SARS-CoV-2 infection induced an attenuated pro-inflammatory cytokines/chemokines induction and type I and type II IFN responses. A single dose of 10 U/mL interferon-β (IFNβ) pretreatment potently protected both Calu3 and Caco2 against SARS-CoV-2 infection. Interestingly, SARS-CoV-2 was more sensitive to the pretreatment with IFNβ and IFN inducer than SARS-CoV in Calu3.
Conclusions |
Despite robust infection in both human lung and intestinal epithelial cells, SARS-CoV-2 could attenuate the virus-induced pro-inflammatory response and IFN response. Pre-activation of the type I IFN signaling pathway primed a highly efficient antiviral response in the host against SARS-CoV-2 infection, which could serve as a potential therapeutic and prophylactic maneuver to COVID-19 patients.
Le texte complet de cet article est disponible en PDF.Key words : SARS-CoV-2, COVID-19, Innate immune response, IFN
Plan
Vol 81 - N° 4
P. e1-e10 - octobre 2020 Retour au numéro
Article précédent
- Investigation of a family outbreak of COVID-19 using systematic rapid diagnostic tests raises new questions about transmission
- Thierry Prazuck, Susanna Giaché, Camelia Gubavu, Mathilda Colin, Vincent Rzepecki, Aymeric Sève, Gilles Pialoux, Laurent Hocqueloux
- Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis
- Roberto Rossotti, Giovanna Travi, Nicola Ughi, Matteo Corradin, Chiara Baiguera, Roberto Fumagalli, Maurizio Bottiroli, Michele Mondino, Marco Merli, Andrea Bellone, Andriano Basile, Ruggero Ruggeri, Fabrizio Colombo, Mauro Moreno, Stefano Pastori, Carlo Federico Perno, Paolo Tarsia, Oscar Massimiliano Epis, Massimo Puoti, Niguarda COVID-19 Working Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.